These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 33147589

  • 1. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE, Minović I, van Faassen M, Kema IP, Boertien WE, Bakker SJL, van Beek AP, Gansevoort RT.
    Am J Nephrol; 2020; 51(11):861-870. PubMed ID: 33147589
    [Abstract] [Full Text] [Related]

  • 2. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1749-56. PubMed ID: 26231191
    [Abstract] [Full Text] [Related]

  • 3. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.
    Am J Kidney Dis; 2019 Mar 07; 73(3):354-362. PubMed ID: 30578153
    [Abstract] [Full Text] [Related]

  • 4. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
    Zittema D, Casteleijn NF, Bakker SJ, Boesten LS, Duit AA, Franssen CF, Gaillard CA, Gansevoort RT.
    PLoS One; 2017 Mar 07; 12(1):e0169263. PubMed ID: 28081165
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT.
    Clin J Am Soc Nephrol; 2011 Feb 07; 6(2):361-8. PubMed ID: 20930090
    [Abstract] [Full Text] [Related]

  • 8. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 07; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 9. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT.
    Clin J Am Soc Nephrol; 2012 Jun 07; 7(6):906-13. PubMed ID: 22516290
    [Abstract] [Full Text] [Related]

  • 10. Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.
    Katz DA, Liu W, Locke C, Dutta S, Tracy KA.
    Psychopharmacology (Berl); 2016 Jan 07; 233(1):71-81. PubMed ID: 26407603
    [Abstract] [Full Text] [Related]

  • 11. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O, Torres VE.
    Curr Opin Nephrol Hypertens; 2013 Jul 07; 22(4):459-70. PubMed ID: 23736843
    [Abstract] [Full Text] [Related]

  • 12. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
    Casteleijn NF, Messchendorp AL, Bae KT, Higashihara E, Kappert P, Torres V, Meijer E, Leliveld AM.
    Clin Exp Nephrol; 2017 Jun 07; 21(3):375-382. PubMed ID: 27339446
    [Abstract] [Full Text] [Related]

  • 13. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul 07; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 14. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In adults with obesity, copeptin is linked with BMI but is not associated with long-term exposure to cortisol and cortisone.
    van der Valk ES, van der Voorn B, Iyer AM, van den Berg SAA, Savas M, de Rijke YB, van den Akker ELT, Melander O, van Rossum EFC.
    Eur J Endocrinol; 2020 Dec 19; 183(6):669-676. PubMed ID: 33112256
    [Abstract] [Full Text] [Related]

  • 17. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 18. Hypothalamic-pituitary-adrenal axis suppression - The value of salivary cortisol and cortisone in assessing hypothalamic-pituitary-adrenal recovery.
    Kalaria T, Agarwal M, Kaur S, Hughes L, Sharrod-Cole H, Chaudhari R, Gherman-Ciolac C, Chopra R, Okeke V, Ford C, Buch H, Gama R.
    Ann Clin Biochem; 2020 Nov 06; 57(6):456-460. PubMed ID: 32961064
    [Abstract] [Full Text] [Related]

  • 19. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.
    Am J Kidney Dis; 2011 May 06; 57(5):692-9. PubMed ID: 21333426
    [Abstract] [Full Text] [Related]

  • 20. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
    Wang X, Constans MM, Chebib FT, Torres VE, Pellegrini L.
    Am J Nephrol; 2019 May 06; 49(6):487-493. PubMed ID: 31117065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.